PHASE I DOSE ESCALATION STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS WITH ANV419, A NOVEL FUSION PROTEIN SELECTIVE FOR IL-2R beta/gamma

JOURNAL FOR IMMUNOTHERAPY OF CANCER(2022)

引用 0|浏览3
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要